Scholar Rock expects September PDUFA for spinal muscular atrophy drug to stay unchanged despite CDMO woes 

Scholar Rock is not anticipating any delays to the PDUFA date for its lead asset apitegromab in spinal muscular atrophy, despite issues found at two third-party CDMO sites, with one of these run by Novo ...